FXYD6: a novel therapeutic target toward hepatocellular carcinoma

doi:10.1007/s13238-014-0045-0

Protein Cell

2014, Vol. 5

Issue (7) : 532-543 https://doi.org/10.1007/s13238-014-0045-0

RESEARCH ARTICLE

FXYD6: a novel therapeutic target toward hepatocellular carcinoma

Qian Gao^1,²,Xiongfei Chen³,Hongxia Duan¹,Zhaoqing Wang¹,Jing Feng¹,Dongling Yang¹,Lina Song¹,Ningxin Zhou^4,^*(

),Xiyun Yan^1,^*(

)

1. Key Laboratory of Protein and Peptide Pharmaceuticals, CAS-University of Tokyo Joint Laboratory of Structural Virology and Immunology, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
2. University of Chinese Academy of Sciences, Beijing 100049, China
3. Medical College of Soochow University, Industrial Park, Suzhou 215123, China
4. Institute of Hepatobiliary Gastrointestinal Disease, General Hospital of PLA Second Artillery, Beijing 100088, China

Download: PDF(1329 KB)
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

FXYD6, FXYD domain containing ion transport regulator 6, has been reported to affect the activity of Na⁺/K⁺-ATPase and be associated with mental diseases. Here, we demonstrate that FXYD6 is up-regulated in hepatocellular carcinoma (HCC) and enhances the migration and proliferation of HCC cells. Up-regulation of FXYD6 not only positively correlates with the increase of Na⁺/K⁺-ATPase but also coordinates with the activation of its downstream Src-ERK signaling pathway. More importantly, blocking FXYD6 by its functional antibody significantly inhibits the growth potential of the xenografted HCC tumors in mice, indicating that FXYD6 represents a potential therapeutic target toward HCC. Altogether, our results establish a critical role of FXYD6 in HCC progression and suggest that the therapy targeting FXYD6 can benefit the clinical treatment toward HCC patients.

Keywords FXYD6 hepatocellular carcinoma (HCC) tumor progression therapeutic target Na⁺/K⁺-ATPase Src-ERK signaling pathway

Corresponding Author(s): Ningxin Zhou

Issue Date: 31 July 2014

Cite this article:

Qian Gao,Xiongfei Chen,Hongxia Duan, et al. FXYD6: a novel therapeutic target toward hepatocellular carcinoma[J]. Protein Cell, 2014, 5(7): 532-543.

URL:

https://academic.hep.com.cn/pac/EN/10.1007/s13238-014-0045-0
https://academic.hep.com.cn/pac/EN/Y2014/V5/I7/532

1	Choudhury K, McQuillin A, Puri V, Pimm J, Datta S, Thirumalai S, Krasucki R, Lawrence J, Bass NJ, Quested D (2007) A genetic association study of chromosome 11q22-24 in two different samples implicates the FXYD6 gene, encoding phosphohippolin, in susceptibility to schizophrenia. Am J Hum Genet80: 664-672 doi: 10.1086/513475
2	Delprat B, Puel JL, Geering K (2007a) Dynamic expression of FXYD6 in the inner ear suggests a role of the protein in endolymph homeostasis and neuronal activity. Dev Dyn236: 2534-2540 doi: 10.1002/dvdy.21269
3	Delprat B, Schaert D, Roy S, Wang J, Puel JL, Geering K (2007b) FXYD6 is a novel regulator of Na, K-ATPase expressed in the inner ear. J Biol Chem282: 7450-7456 doi: 10.1074/jbc.M609872200
4	Garty H, Karlish SJD (2006) Role of FXYD proteins in ion transport. Annu Rev Physiol68: 431-459 doi: 10.1146/annurev.physiol.68.040104.131852
5	Gaut JP, Crimmins DL, Lockwood CM, McQuillan JJ, Ladenson JH (2013) Expression of the Na+/K+ -transporting ATPase gamma subunit FXYD2 in renal tumors. Mod Pathol26: 716-724 doi: 10.1038/modpathol.2012.202
6	Geering K (2006) FXYD proteins: new regulators of Na-k-ATPase. Am J Physiol Renal290: F241-F250 doi: 10.1152/ajprenal.00126.2005
7	Grzmil M, Voigt S, Thelen P, Hemmerlein B, Helmke K, Burfeind P (2004) Up-regulated expression of the MAT-8 gene in prostate cancer and its siRNA-mediated inhibition of expression induces a decrease in proliferation of human prostate carcinoma cells. Int J Oncol24: 97-105
8	Han CP, Kok LF, Wang PH, Wu TS, Tyan YS, Cheng YW, Lee MY, Yang SF (2009) Scoring of p16(INK4a) immunohistochemistry based on independent nuclear staining alone can sufficiently distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. Mod Pathol22: 797-806
9	Ino Y, Gotoh M, Sakamoto M, Tsukagoshi K, Hirohashi S (2002) Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis. Proc Natl Acad Sci USA99: 365-370 doi: 10.1073/pnas.012425299
10	Kayed H, Kleeff J, Kolb A, Ketterer K, Keleg S, Felix K, Giese T, Penzel R, Zentgraf H, Buchler MW (2006) FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth. Int J Cancer118: 43-54 doi: 10.1002/ijc.21257
11	Mijatovic T, Ingrassia L, Facchini V, Kiss R (2008) Na+/K+-ATPase alpha subunits as new targets in anticancer therapy. Expert Opin Ther Targets12: 1403-1417 doi: 10.1517/14728222.12.11.1403
12	Mishra NK, Peleg Y, Cirri E, Belogus T, Lifshitz Y, Voelker DR, Apell HJ, Garty H, Karlish SJD (2011) FXYD proteins stabilize Na, K-ATPase amplification of specific phosphatidylserine-protein interactions. J Biol Chem286: 9699-9712 doi: 10.1074/jbc.M110.184234
13	Prassas I, Diamandis EP (2008) Novel therapeutic applications of cardiac glycosides. Nat Rev Drug Discov7: 926-935 doi: 10.1038/nrd2682
14	Sato H, Ino Y, Miura A, Abe Y, Sakai H, Ito K, Hirohashi S (2003) Dysadherin: expression and clinical significance in thyroid carcinoma. J Clin Endocrinol Metab88: 4407-4412 doi: 10.1210/jc.2002-021757
15	Shiina N, Yamaguchi K, Tokunaga M (2010) RNG105 deficiency impairs the dendritic localization of mRNAs for Na+/K+ ATPase subunit isoforms and leads to the degeneration of neuronal networks. J Neurosci30: 12816-12830 doi: 10.1523/JNEUROSCI.6386-09.2010
16	Sweadner KJ, Rael E (2000) The FXYD gene family of small ion transport regulators or channels: cDNA sequence, protein signature sequence, and expression. Genomics68: 41-56 doi: 10.1006/geno.2000.6274
17	Widegren E, Onnesjo S, Arbman G, Kayed H, Zentgraf H, Kleeff J, Zhang H, Sun XF (2009) Expression of FXYD3 protein in relation to biological and clinicopathological variables in colorectal cancers. Chemotherapy55: 407-413 doi: 10.1159/000263227
18	Xu ZW, Wang FM, Gao MJ, Chen XY, Hu WL, Xu RC (2010) Targeting the Na+/K+-ATPase alpha 1 subunit of hepatoma HepG2 cell line to induce apoptosis and cell cycle arresting. Biol Pharm Bull33: 743-751 doi: 10.1248/bpb.33.743

[1]	Zhan-Qi Cao,Xiu-Li Guo. The role of galectin-4 in physiology and diseases[J]. Protein Cell, 2016, 7(5): 314-324.
[2]	Haiyan Chu,Ting Wu,Wenyu Wu,Wenzhen Tu,Shuai Jiang,Sidi Chen,Yanyun Ma,Qingmei Liu,Xiaodong Zhou,Li Jin,Jiucun Wang. Involvement of collagen-binding heat shock protein 47 in scleroderma-associated fibrosis[J]. Protein Cell, 2015, 6(8): 589-598.
[3]	Ming Liu,Lingxi Jiang,Xin-Yuan Guan. The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update[J]. Protein Cell, 2014, 5(9): 673-691.
[4]	Jun Hu, Yaxing Xu, Junli Hao, Saifeng Wang, Changfei Li, Songdong Meng. MiR-122 in hepatic function and liver diseases[J]. Prot Cell, 2012, 3(5): 364-371.
[5]	Hao Ye, Kailin Tang, Linlin Yang, Zhiwei Cao, Yixue Li. Study of drug function based on similarity of pathway fingerprint[J]. Prot Cell, 2012, 3(2): 132-139.

Viewed

Full text

Abstract

Cited

Shared

Discussed